Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A New-Class Antibacterial─Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2011 · External reference
Unresolved reference
2005 · External reference
Antibacterial discovery and development--the failure of success?
10.1038/nbt1206-1497 · 2006 · External reference
Challenges of antibacterial discovery revisited
10.1111/j.1749-6632.2010.05828.x · 2010 · External reference
Infectious Diseases Society of America The 10 x ’20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020
10.1086/652237 · 2010 · External reference
The current problem of staphylococcal infections
10.7326/0003-4819-45-5-748 · 1956 · External reference
Clinical observations on the use of novobiocin in penicillin-resistant staphylococcal septicemia
1957 · External reference
The common identity of cathomycin and Streptonivicin
1955 · External reference
Antibacterial activity of Streptonivicin and cathomycin, two new antibiotics
1956 · External reference
Novobiocin and several of its derivatives
1956 · External reference
Two new antibiotics: antibacterial activity of novobiocin and vancomycin
10.1016/s0140-6736(56)90052-6 · 1956 · External reference
Current therapeutics. CXIV. Novobiocin
1957 · External reference
Studies on coumermycin, a new Antibiotic. I. Production, isolation and characterization of coumermycin A1
1965 · External reference
Novobiocin
10.1159/000386637 · 1957 · External reference
Some aspects of novobiocin action on Escherichia coli and Staphylococcus aureus
10.1007/bf02146985 · 1968 · External reference
Novobiocin
1959 · External reference
The current status of erythromycin, kanamycin, novobiocin, oleandomycin, ristocetin, and vancomycin, with particular reference to their use in staphylococcal disease; panel discussion
1959 · External reference
Clinical effectiveness and safety of novobiocin
1956 · External reference
Coumarin-glycoside antibiotics
10.1016/s0301-4770(08)60948-3 · 1978 · External reference
The panalba story.
1969 · External reference
FDA and Panalba: a conflict of commercial, therapeutic goals?
10.1126/science.165.3896.875 · 1969 · External reference
Novobiocin; serum concentrations and urinary excretion following oral administration in man
1956 · External reference
A clinical evaluation of the parenteral use of novobiocin
10.1097/00000441-195809000-00007 · 1958 · External reference
Clinical and laboratory studies of novobiocin, a new antibiotic
10.1001/archinte.1956.00250250007001 · 1956 · External reference
Agranulocytosis associated with novobiocin administration: report of a case
10.7326/0003-4819-46-4-778 · 1957 · External reference
Novobiocin jaundice: demonstration of a hemolytic state
1960 · External reference
Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome
10.1128/aac.37.6.1334 · 1993 · External reference
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study
10.1016/s1083-8791(00)70059-0 · 2000 · External reference
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies
2000 · External reference
Clin-Alert: October 4, 1969
10.1177/006947706900700119 · 1969 · External reference
Unresolved reference
1960 · External reference
Antibiotic approach
1958 · External reference
Production, isolation, and synthesis of the coumermycins (sugordomycins), a new streptomycete antibiotic complex
1965 · External reference
Structure-activity relationships in coumermycins
10.1016/s0065-2164(08)70094-7 · 1972 · External reference
Chemotherapeutic properties of coumermycin A1
1965 · External reference
Microbiological and pharmacological study of a new antibiotics, coumermycin A1
1969 · External reference
Pharmacokinetic profile of coumermycin A1
10.1002/jps.2600590306 · 1970 · External reference
Coumermycin A1: biopharmaceutical studies II
10.1002/jps.2600590906 · 1970 · External reference
Unresolved reference
1970 · External reference
Structure-activity relationships in chemically modified coumermycin
10.1351/pac197128040571 · 1971 · External reference
Microbiological and pharmacological evaluation of BL-C 43, a new semisynthetic derivative of coumermycin A1
1969 · External reference
Unresolved reference
External reference
A selective cleavage of the oxazole moiety in noviosylcoumarin antibiotics. A new process to key intermediates for coumermycin analog synthesis
10.1021/jo00256a037 · 1988 · External reference
Synthesis and in vitro activity of new semi-synthetic coumermycin analogs: chemical modification at the C-3 amide
10.7164/antibiotics.42.1379 · 1989 · External reference
Synthesis and in vitro antibacterial activity of new semi-synthetic noviosylcoumarin antibiotics: chemical modification at the C-3′ ester
10.1016/s0960-894x(01)80578-3 · 1994 · External reference
Activity of novobiocin against methicillin-resistant Staphylococcus aureus
10.1093/jac/15.4.435 · 1985 · External reference
Should novobiocin be clinically re-evaluated?
10.1016/0732-8893(89)90105-3 · 1989 · External reference
Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination
10.1016/0732-8893(93)90024-2 · 1993 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Cyclothialidine and its congeners: A new class of DNA gyrase inhibitors
10.1016/0163-7258(93)90017-8 · 1993 · External reference
Biological characterization of cyclothialidine, a new DNA gyrase inhibitor
10.1128/aac.37.12.2656 · 1993 · External reference
Unresolved reference
External reference
From the DNA gyrase inhibitor cyclothialidine to a new class of antibacterial agents
10.2533/000942903777679505 · 2003 · External reference
Unresolved reference
External reference
Seco-cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties
10.1021/jm0010623 · 2001 · External reference
GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin
10.1128/aac.40.4.1060 · 1996 · External reference
Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase
10.1128/aac.40.2.473 · 1996 · External reference
The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography
10.1002/j.1460-2075.1996.tb00483.x · 1996 · External reference
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine
10.1021/jm0310232 · 2004 · External reference
A new DNA gyrase inhibitor subclass of the cyclothialidine familybased on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties
10.1021/jm1014023 · 2011 · External reference
DNA gyrase: an enzyme that introduces superhelical turns into DNA
10.1073/pnas.73.11.3872 · 1976 · External reference
Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase
10.1073/pnas.73.12.4474 · 1976 · External reference
Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
10.1073/pnas.74.11.4772 · 1977 · External reference
New topoisomerase essential for chromosome segregation in E. coli
10.1016/0092-8674(90)90172-b · 1990 · External reference
Purification and characterization of DNA topoisomerase IV in Escherichia coli
10.1016/s0021-9258(18)35660-6 · 1992 · External reference
DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity
10.1128/aac.32.8.1192 · 1988 · External reference
DNA cloning and organization of the Staphylococcus aureus gyrA and gyrB genes: close homology among gyrase proteins and implications for 4-quinolone action and resistance
10.1128/jb.172.6.3481-3484.1990 · 1990 · External reference
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones
10.1111/j.1365-2958.1994.tb00458.x · 1994 · External reference
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
10.1128/aac.42.11.2810 · 1998 · External reference
Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones
10.1128/aac.43.5.1129 · 1999 · External reference
In front of and behind the replication fork: bacterial type IIA topoisomerases
10.1007/s00018-010-0299-5 · 2010 · External reference
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases
10.1038/nsmb.1604 · 2009 · External reference
Type IIA topoisomerase inhibition by a new class of antibacterial agents
10.1038/nature09197 · 2010 · External reference
Mechanisms of action and resistance of older and newer fluoroquinolones
10.1086/314056 · 2000 · External reference
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance
10.1073/pnas.94.25.13991 · 1997 · External reference
Unresolved reference
2006 · External reference
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds
10.1128/aac.00596-06 · 2007 · External reference
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
10.1093/jac/dkn528 · 2009 · External reference
Unresolved reference
2012 · External reference
Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
10.1016/j.tim.2014.04.007 · 2014 · External reference
Studies on mutational cross-resistance between ciprofloxacin, novobiocin and coumermycin in Escherichia coli and Staphylococcus warneri
1993 · External reference
Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth
10.1128/aac.22.4.662 · 1982 · External reference
Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions
10.1016/s0021-9258(20)80551-1 · 1993 · External reference
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class
10.1128/aac.50.4.1228-1237.2006 · 2006 · External reference
New aminocoumarin antibiotics as gyrase inhibitors
10.1016/j.ijmm.2013.08.013 · 2014 · External reference
Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies
10.1093/jac/dkm191 · 2007 · External reference
Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus
10.1128/aac.49.9.3810-3815.2005 · 2005 · External reference
Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus
10.1016/j.chembiol.2011.06.011 · 2011 · External reference
Quinolone-mediated bacterial death
10.1128/aac.01617-06 · 2008 · External reference
Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases
10.1128/aac.00719-13 · 2013 · External reference
Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis
10.1093/jac/dku379 · 2014 · External reference
Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections
10.1086/381972 · 2004 · External reference
Crystal structure of an N-terminal fragment of the DNA gyrase B protein
10.1038/351624a0 · 1991 · External reference
The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin
10.1002/(sici)1097-0134(199705)28:1<41::aid-prot4>3.3.co;2-b · 1997 · External reference
Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase
10.1074/jbc.m506520200 · 2005 · External reference
GHKL, an emergent ATPase/kinase superfamily
10.1016/s0968-0004(99)01503-0 · 2000 · External reference
In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis
10.1083/jcb.143.4.901 · 1998 · External reference
Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair
10.1016/s0092-8674(00)80717-5 · 1999 · External reference
Structure and function of the N-terminal 40 kDa fragment of human PMS2: a monomeric GHL ATPase
10.1093/emboj/20.19.5521 · 2001 · External reference
Molecular basis of bacterial outer membrane permeability revisited
10.1128/mmbr.67.4.593-656.2003 · 2003 · External reference
Challenges of antibacterial discovery
10.1128/cmr.00030-10 · 2011 · External reference
Semisynthetic coumermycins: structure-activity relationships
10.1128/am.19.1.14-26.1970 · 1970 · External reference
Novenamine is the active moiety in novobiocin
1986 · External reference
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)
10.1021/jm500462x · 2014 · External reference
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV
10.1016/j.bmcl.2012.05.128 · 2012 · External reference
Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents
10.1371/journal.pone.0084409 · 2013 · External reference
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
10.1016/j.bmcl.2012.11.032 · 2013 · External reference
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity
10.1016/j.bmcl.2012.11.073 · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples
10.1128/aac.37.7.1393 · 1993 · External reference
Physicochemical properties of antibacterial compounds: implications for drug discovery
10.1021/jm700967e · 2008 · External reference
Outer membrane permeability and antibiotic resistance
10.1016/j.bbapap.2008.11.005 · 2009 · External reference
Substrate specificity and kinetics of bacterial transmembrane transporters
10.4172/2155-9585.1000e105 · 2012 · External reference
Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli
10.1073/pnas.0901695106 · 2009 · External reference
Development of a liquid chromatography/mass spectrometry-based drug acumulation assay in Pseudomonas aeruginosa
10.1016/j.ab.2008.10.041 · 2009 · External reference
General platform for systematic quantitative evaluation of small-molecule permeability in bacteria
10.1021/cb5003015 · 2014 · External reference
Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery
10.1021/jm201275d · 2012 · External reference
Unresolved reference
External reference
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B
10.1016/s0960-894x(99)00492-8 · 1999 · External reference
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B
10.1016/s0960-894x(99)00329-7 · 1999 · External reference
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose
10.1016/s0960-894x(99)00493-x · 1999 · External reference
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere
10.1016/s0960-894x(99)00654-x · 2000 · External reference
Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkylnoviose: biological activity of RU79115
10.1016/s0960-894x(00)00304-8 · 2000 · External reference
Noviose mimics of the coumarin inhibitors of gyrase B
10.1016/j.tetlet.2003.10.076 · 2003 · External reference
Synthesis of the 4′-desmethoxy analogue of RU79115
10.2298/jsc0411855m · 2004 · External reference
Fine Tuning of physico-chemical parameters to optimize a new series of novobiocin analogues
10.1016/s0960-894x(01)00257-8 · 2001 · External reference
DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose
10.1021/bi0159837 · 2002 · External reference
Unresolved reference
External reference
Design, synthesis and evaluation of a novel series of spiroketals based on the structure of the antibacterial gyrase inhibitor novobiocin
10.1039/a700647k · 1997 · External reference
Unresolved reference
External reference
Unresolved reference
2001 · External reference
Isothermal titration calorimetry in drug discovery
10.1016/s0079-6468(08)70097-3 · 2001 · External reference
Design, synthesis, and structure–activity relationship studies of ATP analogues as DNA gyrase inhibitors
10.1016/s0960-894x(00)00109-8 · 2000 · External reference
Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening
10.1021/jm000017s · 2000 · External reference
Design, synthesis, and structure–activity relationship studies of new phenolic DNA gyrase inhibitors
10.1016/j.bmcl.2006.12.065 · 2007 · External reference
Potent DNA gyrase inhibitors; novel 5-vinylpyrazole analogues with Gram-positive antibacterial activity
10.1016/j.bmcl.2004.03.045 · 2004 · External reference
Design, synthesis and structure–activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity
10.1016/j.bmcl.2004.03.044 · 2004 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase
10.1016/j.bmcl.2010.03.052 · 2010 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Structure-activity relationship (SAR): effort towards blocking N-glucuronidation of indazoles (PF-03376056) by human UGT1A enzymes
10.2174/187231209787176371 · 2009 · External reference
Unresolved reference
External reference
Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines
10.1016/j.ijantimicag.2012.12.001 · 2013 · External reference
Unresolved reference
External reference
Tools to define the relevance of PK/PD parameters to the efficacy, toxicity, and emergence of resistance of antimicrobials
2007 · External reference
Unresolved reference
External reference
Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay
10.1177/1087057113487208 · 2013 · External reference
Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents
10.1128/aac.05485-11 · 2012 · External reference
Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy
10.1016/j.bmcl.2011.10.010 · 2011 · External reference
Novel DNA gyrase inhibitors: microbiological characterisation of pyrrolamides
10.1016/j.ijantimicag.2012.08.017 · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Crystal structures of Escherichia coli topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase
10.1128/aac.48.5.1856-1864.2004 · 2004 · External reference
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships
10.1021/jm800318d · 2008 · External reference
Unresolved reference
External reference
Evaluation of WO2012177707 and WO2012097269: Vertex’s phosphate prodrugs of gyrase and topoisomerase antibacterial agents
10.1517/13543776.2013.820707 · 2013 · External reference
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy
10.1016/j.bmcl.2014.03.022 · 2014 · External reference
Second-generation antibacterial benimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability
10.1021/jm500563g · 2014 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV
10.1016/j.bmcl.2009.07.141 · 2009 · External reference
Unresolved reference
External reference
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity
10.1016/j.bmcl.2008.11.102 · 2009 · External reference
10.1039/9781849734912-00335
10.1039/9781849734912-00335 · 2012 · External reference
Unresolved reference
External reference
Design, synthesis and biological evaluation of alpha-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors
10.1016/j.bmcl.2013.10.058 · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents
10.1021/jm401208b · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity
10.1016/j.ejmech.2014.08.025 · 2014 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework
10.1038/nrd4309 · 2014 · External reference
TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties
10.1016/s0968-0896(03)00126-3 · 2003 · External reference
Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent
10.1016/j.ejmech.2011.01.014 · 2011 · External reference
Protein binding: do we ever learn?
10.1128/aac.01433-10 · 2011 · External reference
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents
10.1128/cmr.00092-12 · 2013 · External reference
Drugs for bad bugs: confronting the challenges of antibacterial discovery
10.1038/nrd2201 · 2007 · External reference
Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode
10.1016/j.chembiol.2014.10.015 · 2014 · External reference
Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase
10.1002/chem.201202645 · 2012 · External reference
Why is big Pharma getting out of antibacterial drug discovery?
10.1016/j.mib.2003.08.003 · 2003 · External reference
Unresolved reference
External reference
Unresolved reference
1999 · External reference
Unresolved reference
1980 · External reference
Unresolved reference
1975 · External reference
10.1093/oso/9780199534845.003.0006
10.1093/oso/9780199534845.003.0006 · 2008 · External reference
Symposium: How a Drug is Born
1961 · External reference
10.1017/cbo9780511511677
10.1017/cbo9780511511677 · 2004 · External reference
Round table: are new antibiotics needed?
1965 · External reference
Recent developments of antibiotic research and classification of antibiotics according to chemical structure
10.1016/s0065-2164(08)70573-2 · 1974 · External reference
Finding the gems using genomic discovery: antibacterial drug discovery strategies - the successes and the challenges
10.1016/j.ddstr.2004.11.003 · 2005 · External reference
Antibiotics in the clinical pipeline in 2013
10.1038/ja.2013.86 · 2013 · External reference
Can biotech deliver new antibiotics?
10.1016/j.mib.2005.08.007 · 2005 · External reference
Unresolved reference
External reference
The cancer drug that almost wasn’t
10.1126/science.345.6199.865 · 2014 · External reference
The challenge of antimicrobial resistance: new regulatory tools to support product development
10.1038/clpt.2014.107 · 2014 · External reference
US Capitol Capsule: What’s Life & Limb Worth? Gauging Antibiotic’s Value
2014 · External reference
The value of single-pathogen antibacterial agents
10.1038/nrd3957-c1 · 2013 · External reference
Antibiotic Trial Network Could Emerge from FDA/NIH Workshop
2014 · External reference
The future of antibiotics
10.1186/cc13948 · 2014 · External reference
Structure of an ‘open’ clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport
10.1093/nar/gkt749 · 2013 · External reference
Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center
10.1074/jbc.275.13.9468 · 2000 · External reference
Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity
10.1038/nsmb.2388 · 2012 · External reference
Coumarin antibiotic binding to human albumin
10.1016/0006-2952(81)90629-8 · 1981 · External reference
Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics
10.1093/jac/dkr247 · 2011 · External reference
BDDCS applied to over 900 drugs
10.1208/s12248-011-9290-9 · 2011 · External reference
